Gene row deepens as Myriad countersues OncorMed
This article was originally published in Clinica
Executive Summary
The row over the BRCA1 breast cancer susceptibility gene deepened last week as Myriad Genetics was awarded a US patent for the breast cancer gene and immediately countersued its genomics rival OncorMed for breaching it.